Settlements which date from c. 2200–1700 BCE in the Bactria and Margiana contained elaborate ritual structures with rooms containing everything needed for making drinks containing extracts from poppy (opium), hemp (cannabis), and ephedra (which contains ephedrine).[113] Although there is no evidence of ephedra being used by steppe tribes, they engaged in cultic use of hemp. Cultic use ranged from Romania to the Yenisei River and had begun by 3rd millennium BC Smoking hemp has been found at Pazyryk.[114]

Another claim is that Mellon, Secretary of the Treasury and the wealthiest man in America at that time, had invested heavily in DuPont's new synthetic fiber, nylon, and believed[dubious – discuss] that the replacement of the traditional resource, hemp, was integral to the new product's success.[121][126][127][128][129][130][131][132] The company DuPont and many industrial historians dispute a link between nylon and hemp, nylon became immediately a scarce commodity.[clarification needed] Nylon had characteristics that could be used for toothbrushes (sold from 1938) and very thin nylon fiber could compete with silk and rayon in various textiles normally not produced from hemp fiber, such as very thin stockings for women.[125][133][134][135][136]
In recent decades, the neurobiology of cannabinoids has been analyzed.[12-15] The first cannabinoid receptor, CB1, was identified in the brain in 1988. A second cannabinoid receptor, CB2, was identified in 1993. The highest expression of CB2 receptors is located on B lymphocytes and natural killer cells, suggesting a possible role in immunity. Endogenous cannabinoids (endocannabinoids) have been identified and appear to have a role in pain modulation, control of movement, feeding behavior, mood, bone growth, inflammation, neuroprotection, and memory.[16] 

Cannabis Pain Relief Product

The basic commercial options for growing hemp in North America is as a fiber plant, an oilseed crop, or for dual harvest for both seeds and fiber. Judged on experience in Canada to date, the industry is inclined to specialize on either fiber or grain, but not both. Hemp in our opinion is particularly suited to be developed as an oilseed crop in North America. The first and foremost breeding goal is to decrease the price of hempseed by creating more productive cultivars. While the breeding of hemp fiber cultivars has proceeded to the point that only slight improvements can be expected in productivity in the future, the genetic potential of hemp as an oilseed has scarcely been addressed. From the point of view of world markets, concentrating on oilseed hemp makes sense, because Europe has shown only limited interest to date in developing oilseed hemp, whereas a tradition of concentrating on profitable oilseed products is already well established in the US and Canada. Further, China’s supremacy in the production of high-quality hemp textiles at low prices will be very difficult to match, while domestic production of oilseeds can be carried out using technology that is already available. The present productivity of oilseed hemp—about 1 t/ha under good conditions, and occasional reports of 1.5 to 2 t/ha, is not yet sufficient for the crop to become competitive with North America’s major oilseeds. We suggest that an average productivity of 2 t/ha will be necessary to transform hempseed into a major oilseed, and that this breeding goal is achievable. At present, losses of 30% of the seed yields are not uncommon, so that improvements in harvesting technology should also contribute to higher yields. Hemp food products cannot escape their niche market status until the price of hempseed rivals that of other oilseeds, particularly rapeseed, flax, and sunflower. Most hemp breeding that has been conducted to date has been for fiber characteristics, so that there should be considerable improvement possible. The second breeding goal is for larger seeds, as these are more easily shelled. Third is breeding for specific seed components. Notable are the health-promoting gamma-linolenic acid; improving the amino acid spectrum of the protein; and increasing the antioxidant level, which would not only have health benefits but could increase the shelf life of hemp oil and foods.
If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
The main psychoactive constituent of Cannabis was identified as delta-9-tetrahydrocannabinol (THC). In 1986, an isomer of synthetic delta-9-THC in sesame oil was licensed and approved for the treatment of chemotherapy -associated nausea and vomiting under the generic name dronabinol. Clinical trials determined that dronabinol was as effective as or better than other antiemetic agents available at the time.[8] Dronabinol was also studied for its ability to stimulate weight gain in patients with AIDS in the late 1980s. Thus, the indications were expanded to include treatment of anorexia associated with human immunodeficiency virus infection in 1992. Clinical trial results showed no statistically significant weight gain, although patients reported an improvement in appetite.[9,10] Another important cannabinoid found in Cannabis is CBD.[11] This is a nonpsychoactive cannabinoid, which is an analog of THC.
Newer antiemetics (e.g., 5-HT3 receptor antagonists) have not been directly compared with Cannabis or cannabinoids in cancer patients. However, the Cannabis-extract oromucosal spray, nabiximols, formulated with 1:1 THC:CBD was shown in a small pilot randomized, placebo-controlled, double-blinded clinical trial in Spain to treat chemotherapy-related N/V.[39][Level of evidence: 1iC] ASCO antiemetic guidelines updated in 2017 states that evidence remains insufficient to recommend medical marijuana for either the prevention or treatment of N/V in patients with cancer who receive chemotherapy or radiation therapy.[30]
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Hemp Products